UNSPSC 51111625: Azacitidine

This classification denotes a pyrimidine antagonist with the molecular formula C8H12N4O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier M801H13NRU, chemically known as 1,3,5-triazin-2 (1h)-one, 4-amino-1-.beta.-d-ribofuranosyl- but generally known as azacitidine, which bears US NIH Compound Identifier 1805. European Medicines Agency schedules Azacitidine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05624MIG.

UNSPSC 51111625 Azacitidine, a Commodity code, represents pharmaceutical products—specifically azacitidine, a cancer therapeutic—that state and local governments procure primarily through health and human services agencies managing Medicaid, state employee health plans, and correctional or institutional health systems. Recent state-level activity shows purchasing bodies exploring direct-to-manufacturer contracting models and alternative pharmacy benefit arrangements to manage drug costs and improve prescription fulfillment efficiency, moving away from traditional pharmacy benefit manager (PBM) and group purchasing organization (GPO) intermediaries.

The Texas Health and Human Services Commission issued a Request for Information (RFI) No. HHS0017013 on March 27, 2026, with a response deadline of April 3, 2026, to solicit vendor capabilities regarding a Therapeutic Pharmacy Initiative (TPI) Direct-to-Manufacturer Prescriptions program. This RFI seeks information about vendors' experience with direct contracting for self-insured employers and health plans, flexibility to negotiate contracts using negotiated net pricing models without rebates, and capability to implement value-based or outcomes-based agreements. The RFI is exploratory in nature, designed to inform the state's future procurement strategy before issuing formal competitive solicitations; no award values, budget ranges, or formal evaluation criteria are specified at this stage. The open inquiry suggests that state health agencies are actively reassessing pharmaceutical procurement channels and pricing models, particularly for high-cost specialty drugs like azacitidine, though formalized solicitations for specific drug products under this code remain limited in the recent public record.